The advantages and disadvantages of serpatinib and platinib

Serpatinib and platinib are two therapeutic drugs targetingRET gene mutations or fusions. They have some differences in efficacy, indications and side effects.

According to early study data, in patients with RET fusion-positive metastatic non-small cell lung cancer (NSCLC), the objective response rate of serpatinib is as high as 85%, while the objective response rate of platinib is 70%. This suggests that serpatinib may have a higher tumor shrinkage effect during the initial treatment phase. However, in treatment-experienced patients, the objective response rates of both drugs decreased, but serpatinib still maintained a relatively high response rate.

In terms of progression-free survival, serpatinib can achieve17.5 months, which is significantly better than platinib's 9.1 months. This means patients taking serpatinib may have their disease stabilized for longer, reducing the risk of their condition worsening.

Both drugs are mainly used to treat RET fusion-positive metastatic non-small cell lung cancer and medullary thyroid cancer. However, there may be slight differences in specific indications, and the appropriate drug needs to be selected based on the patient's specific situation and type of genetic mutation.

For patients with RET-rearranged lung cancer with brain metastases, both serpatinib and platinib can cross the blood-brain barrier and show clinical intracranial responses. However, the intracranial response rate of serpatinib was significantly higher than that of platinib, reaching 82%, including a complete response rate of 23%. In comparison, the intracranial response rate for platinib was only 56%. This suggests that serpatinib may have a more significant effect in controlling brain metastases.

References:

https://pubmed.ncbi.nlm.nih.gov/36572992/